Instil Bio Inc
TIL24.740USD
+2.510+11.29%
收盤 08/04, 16:00（美東）報價延遲15分鐘
162.27M總市值
虧損本益比TTM
關於 Instil Bio Inc 公司
Instil Bio, Inc. 是一家臨牀階段的生物製藥公司，專注於開發一系列新型療法。該公司尋求獲得許可/收購和開發具有重大未滿足醫療需求的疾病的新型治療候選藥物。其首個此類項目是用於治療癌症的工程化腫瘤浸潤淋巴細胞 (TIL) 細胞療法。該公司正利用其共刺激抗原受體 (CoStAR) 平臺開發一類新型基因工程 TIL 療法。該公司的主要 CoStAR-TIL 候選產品 ITIL-306 表達一種 CoStAR 分子，旨在識別葉酸受體 α (Fra)，這是一種腫瘤相關抗原，在許多實體瘤中表達，包括卵巢癌、子宮癌、非小細胞肺癌和腎癌。CAR-T 和 TCR-T 療法是由經過基因工程改造的 T 細胞組成的細胞產品，可識別腫瘤細胞表面的特定癌症相關抗原。
公司簡介
公司代碼TIL
公司名稱Instil Bio Inc
上市日期Mar 19, 2021
CEOMr. Bronson Crouch
員工數量14
證券類型Ordinary Share
年結日Mar 19
公司地址3963 Maple Avenue
城市DALLAS
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編75219
電話19724993350
網址https://instilbio.com/
公司代碼TIL
上市日期Mar 19, 2021
CEOMr. Bronson Crouch
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
160.00K
--
Mr. Bronson Crouch
Mr. Bronson Crouch
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
116.89K
-77.46%
Dr. George Matcham, Ph.D.
Dr. George Matcham, Ph.D.
Independent Director
Independent Director
30.00K
-21.26%
Mr. R. Kent Mcgaughy, Jr.
Mr. R. Kent Mcgaughy, Jr.
Independent Director
Independent Director
--
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
160.00K
--
Mr. Bronson Crouch
Mr. Bronson Crouch
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
116.89K
-77.46%
Dr. George Matcham, Ph.D.
Dr. George Matcham, Ph.D.
Independent Director
Independent Director
30.00K
-21.26%
Mr. R. Kent Mcgaughy, Jr.
Mr. R. Kent Mcgaughy, Jr.
Independent Director
Independent Director
--
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Curative Ventures Management LLC
28.95%
Vivo Capital, LLC
8.93%
BML Capital Management LLC
6.35%
CPMG, Inc.
6.26%
Balyasny Asset Management LP
4.84%
Other
44.67%
持股股東
持股股東
佔比
Curative Ventures Management LLC
28.95%
Vivo Capital, LLC
8.93%
BML Capital Management LLC
6.35%
CPMG, Inc.
6.26%
Balyasny Asset Management LP
4.84%
Other
44.67%
股東類型
持股股東
佔比
Venture Capital
38.38%
Hedge Fund
18.62%
Investment Advisor
14.63%
Individual Investor
4.68%
Investment Advisor/Hedge Fund
4.61%
Research Firm
2.32%
Corporation
1.83%
Private Equity
1.78%
Pension Fund
0.34%
Other
12.81%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
139
5.72M
87.19%
-1.80M
2025Q1
177
6.10M
93.36%
-1.38M
2024Q4
187
6.08M
93.21%
-646.76K
2024Q3
221
6.16M
94.70%
+69.47K
2024Q2
217
4.68M
71.90%
-1.71M
2024Q1
222
4.70M
72.22%
-1.19M
2023Q4
226
4.39M
67.44%
-1.16M
2023Q3
227
4.47M
68.70%
-1.13M
2023Q2
230
4.57M
70.22%
-1.44M
2023Q1
241
4.80M
73.84%
-1.79M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Curative Ventures Management LLC
1.90M
28.95%
-1.00
-0.00%
Apr 02, 2025
Vivo Capital, LLC
585.49K
8.93%
--
--
Mar 31, 2025
BML Capital Management LLC
416.72K
6.35%
+16.72K
+4.18%
Mar 31, 2025
CPMG, Inc.
410.92K
6.26%
+1.00
+0.00%
Apr 02, 2025
Balyasny Asset Management LP
317.32K
4.84%
+255.69K
+414.86%
Mar 31, 2025
Millennium Management LLC
212.24K
3.24%
+158.99K
+298.56%
Mar 31, 2025
Invus Public Equities Advisors, LLC
203.93K
3.11%
+11.50K
+5.98%
Mar 31, 2025
The Vanguard Group, Inc.
168.10K
2.56%
+16.91K
+11.18%
Mar 31, 2025
Laumas (Sandeep)
160.00K
2.44%
--
--
Apr 02, 2025
Goldman Sachs & Company, Inc.
132.43K
2.02%
+5.50K
+4.34%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Tema Oncology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Micro-Cap ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.01%
DFA Dimensional US Core Equity Market ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
iShares Biotechnology ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
Tema Oncology ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
公告日期
類型
比率
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
Dec 05, 2023
Merger
20<1
